<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00039338</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-55994</org_study_id>
    <secondary_id>2008-003396-52</secondary_id>
    <nct_id>NCT00039338</nct_id>
  </id_info>
  <brief_title>Chemotherapy Followed By Surgery Vs Radiotherapy Plus Chemotherapy in Patients With Stage IB or II Cervical Cancer</brief_title>
  <official_title>Randomized Phase III Study Of Neoadjuvant Chemotherapy Followed By Surgery Vs. Concomitant Radiotherapy And Chemotherapy In FIGO Ib2, IIa&gt;4 cm or IIb Cervical Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
      they stop growing or die. Giving chemotherapy drugs before surgery may shrink the tumor so
      that it can be removed during surgery. Radiation therapy uses high-energy x-rays to kill
      tumor cells. Combining radiation therapy with chemotherapy may kill more tumor cells. It is
      not yet known whether chemotherapy is more effective followed by surgery or combined with
      radiation therapy in treating cervical cancer.

      PURPOSE: Randomized phase III trial to compare the effectiveness of chemotherapy followed by
      radical hysterectomy with that of chemotherapy plus radiation therapy in treating patients
      who have stage IB or stage II cervical cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Compare the overall and progression-free survival of patients with stage IB2, IIA, or
           IIB cervical cancer treated with neoadjuvant cisplatin-based chemotherapy followed by
           radical hysterectomy vs standard therapy comprising concurrent radiotherapy and
           cisplatin-based chemotherapy.

        -  Compare the toxicity of these regimens in these patients.

        -  Compare the quality of life of patients treated with these regimens.

      OUTLINE: This is a randomized, multicenter study. Patients are stratified according to
      participating center, FIGO stage, age (18 to 50 vs 51 to 75), and histological subtype
      (adenomatous vs non-adenomatous component). Patients are randomized to 1 of 2 treatment arms.

        -  Arm I: Patients receive neoadjuvant cisplatin-based chemotherapy on day 1. Treatment
           repeats every 21 days. Within 6 weeks after the last chemotherapy course, patients
           undergo a type III-V Piver-Rutledge radical hysterectomy. Patients with positive lymph
           nodes or tumor invasion into the parametria or less than 5 mm from the resection borders
           after surgery receive standard adjuvant external beam radiotherapy once daily, 5 days a
           week, for 5-5.6 weeks (25-28 treatment days) followed by external boost radiotherapy or
           brachytherapy for 1 or 2 days.

        -  Arm II: Patients receive standard therapy comprising radiotherapy as in arm I
           concurrently with cisplatin-based chemotherapy once weekly for 6 weeks. Adjuvant
           hysterectomy is allowed, but not recommended, in case of histologically proven residual
           tumor.

      Treatment in both arms continues in the absence of disease progression or unacceptable
      toxicity. For patients in both arms, cisplatin may be combined with other chemotherapeutics
      as long as the minimum platinum dose is given.

      Quality of life is assessed at baseline and at 6, 12, 18, and 24 months.

      Patients are followed every 3 months for 1 year, every 6 months for 4 years, and then
      annually thereafter.

      PROJECTED ACCRUAL: A total of 686 patients (343 per treatment arm) will be accrued for this
      study within 3.8 years.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>March 2002</start_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival at 5 years</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">686</enrollment>
  <condition>Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>Chemotherapy followed by surgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>neoadjuvant chemotherapy (Cisplatin) followed by surgery (radial hysterectomy)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Radio-chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Concomitant radiotherapy (external radiotherapy combined with external boost or brachytherapy) and chemotherapy (cisplatin)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
    <description>Radial hysterectomy</description>
    <arm_group_label>Chemotherapy followed by surgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>neoadjuvant chemotherapy</intervention_name>
    <description>Experimental arm: minimal cumulative cisplatin dose of 225 mg/m2. Comparator arm: cumulative cisplatin dose of 200-240 mg/m2.</description>
    <arm_group_label>Chemotherapy followed by surgery</arm_group_label>
    <arm_group_label>Radio-chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>brachytherapy</intervention_name>
    <description>Brachytherapy at the end of external radiation. Minimal total dose (external with or without external boost + brachytherapy) of 75 Gy EQD2 to point A. Overall treatment less than 50 days.</description>
    <arm_group_label>Radio-chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <description>Between 45-50 Gy, in fractions of 1.8 to 2 Gy.</description>
    <arm_group_label>Radio-chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <description>Minimal cumulative 225 mg/m2 (experimental arm). Cumulative 200-240 mg/m2 (comparator arm).</description>
    <arm_group_label>Chemotherapy followed by surgery</arm_group_label>
    <arm_group_label>Radio-chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed cervical cancer, including the following subtypes:

               -  Squamous cell carcinoma

               -  Adenosquamous cell carcinoma

               -  Adenocarcinoma (excluding small cell, clear cell, and other rare variants of the
                  classical adenocarcinoma)

          -  FIGO stage IB2, IIA (greater than 4 cm), or IIB

        PATIENT CHARACTERISTICS:

        Age:

          -  18 to 75

        Performance status:

          -  WHO 0-2

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  Absolute neutrophil count greater than 1,500/mm^3

          -  Platelet count greater than 100,000/mm^3

        Hepatic:

          -  Bilirubin less than 1.46 mg/dL

        Renal:

          -  Creatinine clearance greater than 60 mL/min

        Other:

          -  No other prior or concurrent malignancy except adequately treated basal cell skin
             cancer

          -  No psychological, familial, sociological, or geographical condition that would
             preclude study

          -  Not pregnant

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Not specified

        Chemotherapy:

          -  No prior chemotherapy

        Endocrine therapy:

          -  Not specified

        Radiotherapy:

          -  No prior radiotherapy

        Surgery:

          -  Not specified

        Other:

          -  No other concurrent anticancer agent
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fabio Landoni, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Istituto Europeo Di Oncologia, Milano</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alessandro Colombo, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Ospedale Alessandro Manzoni, Lecco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stefano Greggi, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Istituto Nazionale per lo Studio e la Cura dei Tumori, Napoli</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gemma G. Kenter, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Karl-Franzens-University Graz</name>
      <address>
        <city>Graz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Franz Josef Hospital</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Antwerpen</name>
      <address>
        <city>Edegem</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.Z. Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Regional de la Citadelle</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Regional Francois Baclesse</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Europeo Di Oncologia</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Gerardo</name>
      <address>
        <city>Monza</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Per Lo Studio E La Cura Dei Tumori</name>
      <address>
        <city>Naples</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Mauriziano Umberto I</name>
      <address>
        <city>Torino</city>
        <zip>10128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Universitaria</name>
      <address>
        <city>Turin</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale di Circolo e Fondazione Macchi</name>
      <address>
        <city>Varese</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academisch Medisch Centrum at University of Amsterdam</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vrije Universiteit Medisch Centrum</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medisch Spectrum Twente</name>
      <address>
        <city>Enschede</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Medisch Centrum St. Radboud - Nijmegen</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus MC - Daniel den Hoed Cancer Center</name>
      <address>
        <city>Rotterdam</city>
        <zip>3008 AE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Medisch Centrum - Academisch Ziekenhuis</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospitais da Universidade de Coimbra (HUC)</name>
      <address>
        <city>Coimbra</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario San Carlos</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth The Queen Mother Hospital</name>
      <address>
        <city>Margate</city>
        <state>England</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NHS Greater Glasgow and Clyde - Beatson West of Scotland Cancer Centre</name>
      <address>
        <city>Glasgow</city>
        <state>Scotland</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mid Kent Oncology Centre</name>
      <address>
        <city>Maidstone, Kent</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>France</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Portugal</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Argentina</country>
    <country>Poland</country>
  </removed_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 6, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>December 2, 2016</last_update_submitted>
  <last_update_submitted_qc>December 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IB cervical cancer</keyword>
  <keyword>stage IIB cervical cancer</keyword>
  <keyword>stage IIA cervical cancer</keyword>
  <keyword>cervical squamous cell carcinoma</keyword>
  <keyword>cervical adenocarcinoma</keyword>
  <keyword>cervical adenosquamous cell carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

